flx475
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03674567)
Timeline
Indications
Mechanism of action
- C-C chemokine receptor type 4ANTAGONIST
CCR4 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04894994 | Phase 2 | Sep 3, 2021 | RAPT Therepeutics, Inc. |
| NCT04768686 | Phase 2 | May 31, 2021 | Hanmi Pharmaceutical, Merck |
| NCT03674567 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2018 | RAPT Therepeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| RAPT Therepeutics, Inc. | For profit | 2 | 2 | 1 | 2018 |
| Hanmi Pharmaceutical | For profit | 1 | 1 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1